Next stage of collaboration in East Asia gastric cancer treatment
Chinese Clinical Oncology · 2023
DOI: 10.21037/cco-23-33 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese Clinical Oncology, 2023. Verfasst von Tong Xie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cance…. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
East Asia is a high-risk area for gastric cancer (GC). Despite the rapid progress of immunotherapy and target therapy in recent years, the median overall survival (OS) of metastatic GC is still no more than 2 years. Researchers from East Asia are active in GC clinical and molecular investigations. The collaboration of East Asia plays a vital role to further GC development. Cooperation across East Asia used to be led by Japan and South Korea. However, with the tremendous success of Chinese native drug research and development (R&D) in recent years, the new era calls for a next stage for future collaboration. With the abundance of patient resources and supportive policies from the government, China GC researches made breakthroughs in anti-human epidermal growth factor receptor 2 (HER2) drugs development and immunotherapy etc. Native programmed death 1 (PD-1) inhibitors demonstrated favorable outcomes in first-line GC treatment, early phase clinical trials also showed promising results in novel drug development in the scope of biomarker-guided precisive medicine. However, chances and challenges are both upfront to this special region. There is a lack of standardization in diagnostic and treatment protocols across Asian countries, which adds the difficulties in regional clinical trials. Poor developing countries in southeast Asia are unable to support high quality early phase clinical trials and translational studies, resource deficiency may be another challenge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Zitieren
APA
Xie, T., Zhang, Z., Peng, Z., & Shen, L. (2023). Next stage of collaboration in East Asia gastric cancer treatment. Chinese Clinical Oncology. https://doi.org/10.21037/cco-23-33
Vancouver
Xie T, Zhang Z, Peng Z, Shen L. Next stage of collaboration in East Asia gastric cancer treatment. Chinese Clinical Oncology. 2023. doi:10.21037/cco-23-33
BibTeX
@article{Xie2023,
author = {Xie, Tong and Zhang, Zhening and Peng, Zhi and Shen, Lin},
title = {Next stage of collaboration in East Asia gastric cancer treatment},
journal = {Chinese Clinical Oncology},
year = {2023},
doi = {10.21037/cco-23-33}
}
EUVIMED